CD274 and neoplasm: However, because CAdVEC-derived PD-L1 blocker produces minimal circulating levels of the agent, the combination of local PD-L1 blocker followed by systemic administration should augment the initial antitumor activity within the CAdVEC-treated tumor site and support extension and continuation of this response systemically.